A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts

Interaction of insulin‐like growth factor receptor I (IGF‐IR) with its ligands has been reported to induce cell proliferation, transformation and blockade of cell apoptotic functions. IGF‐IR is overexpressed on numerous tumor cell types and its blockade could be of importance for anti‐cancer therapy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2005-01, Vol.113 (2), p.316-328
Hauptverfasser:	Goetsch, Liliane, Gonzalez, Alexandra, Leger, Olivier, Beck, Alain, Pauwels, Petrus J., Haeuw, Jean François, Corvaia, Nathalie
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - immunology Antineoplastic agents Antineoplastic Agents, Phytogenic - pharmacology Biological and medical sciences Breast Neoplasms - pathology Carcinoma, Hepatocellular - pathology Carcinoma, Non-Small-Cell Lung - pathology Cell Cycle - drug effects combined anti‐cancer therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Drug Interactions Female humanized antibody Humans insulin‐like growth factor type I receptor Liver Neoplasms - pathology Lung Neoplasms - pathology Medical sciences Mice Mice, Nude Pharmacology. Drug treatments Receptor, Epidermal Growth Factor - physiology Receptor, IGF Type 1 - immunology Transplantation, Heterologous Tumor Cells, Cultured Tumors Vinblastine - analogs & derivatives Vinblastine - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!